Literature DB >> 7718643

Presenting signs and symptoms in multiple myeloma: high percentages of stage III among patients without apparent myeloma-associated symptoms.

F Ong1, J Hermans, E M Noordijk, P W Wijermans, J C Kluin-Nelemans.   

Abstract

We studied the medical histories of 127 patients diagnosed with multiple myeloma included in a population-based registry of 945 patients with a para-protein or multiple myeloma in the region of the Comprehensive Cancer Center West (CCCW). We defined patients "not immediately diagnosed" or "delayed diagnosis" as those patients in whom myeloma was not included in the initial differential diagnosis. We found that 37% belonged to this category. These patients more often had symptoms not associated with multiple myeloma. Since a surprising 51% of patients with delayed diagnosis turned out to have stage-III myeloma, the physician should be alert to the presence of this disease, despite the fact that co-morbidity may mask its presence.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7718643     DOI: 10.1007/bf01682035

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  9 in total

Review 1.  Advances in the diagnosis and management of myeloma.

Authors:  P R Greipp
Journal:  Semin Hematol       Date:  1992-07       Impact factor: 3.851

Review 2.  Plasma cell dyscrasias: current status.

Authors:  R A Kyle; P A Greipp
Journal:  Crit Rev Oncol Hematol       Date:  1988       Impact factor: 6.312

Review 3.  Solitary plasmacytoma of bone and asymptomatic multiple myeloma.

Authors:  M A Dimopoulos; A Moulopoulos; K Delasalle; R Alexanian
Journal:  Hematol Oncol Clin North Am       Date:  1992-04       Impact factor: 3.722

Review 4.  Staging and kinetics of multiple myeloma.

Authors:  B G Durie
Journal:  Semin Oncol       Date:  1986-09       Impact factor: 4.929

Review 5.  The treatment of multiple myeloma.

Authors:  R Alexanian; M Dimopoulos
Journal:  N Engl J Med       Date:  1994-02-17       Impact factor: 91.245

6.  Presenting features of monoclonal gammopathies: an analysis of 684 newly diagnosed cases. Cooperative Group for the Study and Treatment of Multiple Myeloma.

Authors:  G Ucci; A Riccardi; R Luoni; E Ascari
Journal:  J Intern Med       Date:  1993-08       Impact factor: 8.989

7.  Is the Durie and Salmon diagnostic classification system for plasma cell dyscrasias still the best choice? Application of three classification systems to a large population-based registry of paraproteinemia and multiple myeloma.

Authors:  F Ong; J Hermans; E M Noordijk; J C Kluin-Nelemans
Journal:  Ann Hematol       Date:  1995-01       Impact factor: 3.673

8.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

9.  Risk of disease progression in asymptomatic multiple myeloma.

Authors:  M A Dimopoulos; A Moulopoulos; T Smith; K B Delasalle; R Alexanian
Journal:  Am J Med       Date:  1993-01       Impact factor: 4.965

  9 in total
  7 in total

1.  Diagnostic delay and complications for older adults with multiple myeloma.

Authors:  Christopher R Friese; Gregory A Abel; Lysa S Magazu; Bridget A Neville; Lisa C Richardson; Craig C Earle
Journal:  Leuk Lymphoma       Date:  2009-03

2.  Quality of life assessment in multiple myeloma patients undergoing dose-reduced tandem autologous stem cell transplantation.

Authors:  A Khalafallah; K McDonnell; H U Dawar; I Robertson; D Woods
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-11-28       Impact factor: 2.576

3.  Clinical prediction tools to identify patients at highest risk of myeloma in primary care: a retrospective open cohort study.

Authors:  Constantinos Koshiaris; Ann Van den Bruel; Brian D Nicholson; Sarah Lay-Flurrie; Fd Richard Hobbs; Jason L Oke
Journal:  Br J Gen Pract       Date:  2021-04-06       Impact factor: 5.386

4.  Advanced myeloma masquerading as chronic shoulder pain in a 48-year-old man: a diagnostic dilemma.

Authors:  Rajarshi Bhadra; Teodora Nikova; Meyappan Somasundaram; Keyvan Ravakhah
Journal:  BMJ Case Rep       Date:  2020-05-27

5.  Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network.

Authors:  Debra A Howell; Alexandra G Smith; Andrew Jack; Russell Patmore; Una Macleod; Emma Mironska; Eve Roman
Journal:  BMC Hematol       Date:  2013-10-31

6.  Risk factors and time to symptomatic presentation in leukaemia, lymphoma and myeloma.

Authors:  Debra A Howell; Fiona Warburton; Amanda-Jane Ramirez; Eve Roman; Alexandra G Smith; Lindsay J L Forbes
Journal:  Br J Cancer       Date:  2015-09-01       Impact factor: 7.640

7.  Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis.

Authors:  Constantinos Koshiaris; Jason Oke; Lucy Abel; Brian D Nicholson; Karthik Ramasamy; Ann Van den Bruel
Journal:  BMJ Open       Date:  2018-06-22       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.